Smoking Cessation: Initial Insights into a New Drug

Abstract

Varenicline is a nicotinic receptor partial agonist (α4β2 subtype) suggested to be used in smoking cessation. Initial trials with this drug show a much higher response than the currently available alternatives. Though the most common adverse event is nausea, concerns have been raised about the possible neuropsychiatric complications of this molecule. Also, the possibility of physical dependence needs to be further evaluated